What is the steroid of choice for an adult with viral pneumonia requiring supplemental oxygen or evidence of systemic inflammation?

Steroid of Choice in Viral Pneumonia

For COVID-19 pneumonia requiring oxygen, use dexamethasone 6 mg daily for up to 10 days; for other viral pneumonias (including influenza), avoid corticosteroids entirely as they increase mortality and secondary infections. 1, 2

COVID-19 Pneumonia: Clear Benefit

The evidence for COVID-19 is unequivocal and represents the primary exception to the general rule against steroids in viral pneumonia:

• Dexamethasone 6 mg daily for 10 days is the evidence-based regimen that reduces 28-day mortality from 26% to 23% in patients requiring supplemental oxygen or mechanical ventilation 1
• This benefit only applies to patients with hypoxemia requiring oxygen support—do not use steroids in mild COVID-19 without oxygen requirement as they provide no benefit and may cause harm 2, 3
• If dexamethasone is unavailable, substitute equivalent doses of other corticosteroids (e.g., hydrocortisone 160 mg daily, methylprednisolone 32 mg daily) 2

The Surviving Sepsis Campaign guidelines from 2020 specifically recommend against routine corticosteroid use in COVID-19 pneumonia 4, but these guidelines preceded the landmark RECOVERY trial data. More recent evidence from 2024-2026 consistently supports dexamethasone use in hypoxemic COVID-19 1, 5, 2.

Influenza and Other Viral Pneumonias: Avoid Steroids

Corticosteroids are contraindicated in influenza pneumonia and most other viral respiratory infections:

• Multiple studies demonstrate increased mortality, delayed viral clearance, and higher rates of secondary bacterial pneumonia with steroid use in influenza 6, 5
• The 2020 Annals of Internal Medicine guideline explicitly states: "immunomodulating therapy is not recommended as adjunct treatment in patients with pneumonia" in the pre-COVID context 7
• This harm occurs particularly with high doses or prolonged courses 6

Special Circumstances

Pneumocystis Jirovecii Pneumonia (PCP)

• Low-dose corticosteroids reduce mortality (13% vs 25%) in HIV patients with moderate to severe PCP 1
• This represents the other major exception where steroids benefit viral/atypical pneumonia

Refractory Shock

• If viral pneumonia progresses to refractory septic shock, consider hydrocortisone 200 mg/day (50 mg IV every 6 hours) as "shock-reversal" therapy 4
• The typical regimen is hydrocortisone administered as continuous infusion or intermittent doses 4

Critical Pitfalls to Avoid

1. Do not extrapolate COVID-19 data to other viral pneumonias—the immunopathology differs fundamentally, with influenza showing opposite outcomes 6
2. Timing matters: Steroids given early in mild disease (before oxygen requirement) provide no benefit and risk harm 2
3. Monitor for hyperglycemia, secondary infections, gastrointestinal bleeding, and neuropsychiatric effects with any corticosteroid use 1
4. Do not use steroids routinely in community-acquired pneumonia unless specifically indicated by severe inflammation (CRP-guided) or confirmed COVID-19 with hypoxemia 8, 3

Algorithm for Decision-Making

Step 1: Identify the viral pathogen

• COVID-19 with oxygen requirement → Dexamethasone 6 mg daily
• Influenza → No steroids
• Other viral pneumonia → No steroids (except PCP in HIV)

Step 2: Assess disease severity

• Mild disease without oxygen → No steroids regardless of pathogen
• Hypoxemia requiring oxygen/ventilation in COVID-19 → Dexamethasone indicated

Step 3: Check for complications

• Refractory septic shock → Consider hydrocortisone 200 mg/day regardless of pathogen 4
• ARDS → Corticosteroids may be beneficial 1

The divergent outcomes between COVID-19 and influenza highlight that viral pneumonias are not a homogeneous entity—personalized treatment based on specific pathogen and inflammatory phenotype is essential 6, 8.